公开(公告)号：US5066678A

公开(公告)日：1991-11-19

申请号：US512874

申请日：1990-04-23

申请人： Ian F. Skidmore ,  Lawrence H. C. Lunts ,  Harry Finch ,  Alan Naylor ,  Ian B. Campbell ,  Charles Willbe ,  William L. Mitchell ,  Stephen Swanson ,  Brian D. Judkins

发明人： Ian F. Skidmore ,  Lawrence H. C. Lunts ,  Harry Finch ,  Alan Naylor ,  Ian B. Campbell ,  Charles Willbe ,  William L. Mitchell ,  Stephen Swanson ,  Brian D. Judkins

IPC分类号： C07C307/06 ,  A61K31/135 ,  A61K31/18 ,  C07C213/00 ,  C07C217/08 ,  C07C217/46 ,  C07C233/36 ,  C07C233/43 ,  C07C275/10 ,  C07C275/14 ,  C07C311/04 ,  C07C311/08 ,  C07C311/35

CPC分类号： C07C217/08 ,  C07C311/35 ,  C07C2101/08 ,  C07C2101/14

摘要： The invention relates to compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof; wherein;R.sup.1 and R.sup.2 each independently represent a hydrogen atom or a C.sub.1-3 -alkyl group with the proviso that the sum total of carbon atom in R.sup.1 and R.sup.2 is not more than 4;X represents a direct bond or a C.sub.1-7 alkylene, C.sub.2-7 alkenylene or C.sub.2-7 alkynylene group and Y represents a direct bond or a C.sub.1-6 alkylene C.sub.2-6 alkenylene or C.sub.2-6 alknylene group with the proviso that the sum total of carbon atoms in X and Y is not more than 10;W represents a group ##STR2## wherein Z represents a group R.sup.3 (CH.sub.2).sub.q where q is 0, 1 or 2 and R.sup.3 is a group R.sup.4 CONH--, R.sup.4 NHCONH--, R.sup.4 R.sup.5 NSO.sub.2 NH--, R.sup.6 SO.sub.2 NH-- or --OH;R.sup.4 and R.sup.5 each represent a hydrogen atom or a C.sub.1-3 alkyl group;R.sup.6 represents a C.sub.1-3 alkyl group;R.sup.7 represents a chlorine atom or the group --CF.sub.3 ;A represents a straight or branched C.sub.1-6 alkyl group, a C.sub.3-8 cycloalkyl group, either of which may be saturated or unsaturated, or a C.sub.1-6 alkoxy group, with the proviso that the sum total of carbon atoms in A and Y is not less than 5;having a stimulant action at .beta..sub.2 -adrenoreceptors and are useful in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

公开(公告)号：US4835278A

公开(公告)日：1989-05-30

申请号：US7670

申请日：1987-01-28

申请人： Roger Barrett ,  Clive A. Meerholz ,  Brian D. Judkins

发明人： Roger Barrett ,  Clive A. Meerholz ,  Brian D. Judkins

IPC分类号： C07D211/14 ,  B01J27/10 ,  B01J27/125 ,  B01J27/138 ,  C07B61/00 ,  C07D295/14 ,  C07D295/155

CPC分类号： C07D295/155

摘要： A process is described for the preparation of a compound of formula (2) ##STR1## (wherein R is a C.sub.1-6 alkyl or a C.sub.7-20 aralkyl group) and the salts thereof, which comprises reducing a compound of formula (3) ##STR2## (or a salt thereof), using a reducing system comprising borohydride ions and metal ions selected from lanthanide ions, alkaline earth metal ions or yttrium ions in solution. The reduction system may be provided by a borohydride (e.g. NaBH.sub.4) and a metal salt (e.g. CeCl.sub.3).The ester (2) may then if desired be hydrolyzed to give the parent acid.

摘要翻译： 描述了制备式（2）化合物（2）（其中R是C 1-6烷基或C 7-20芳烷基）及其盐的方法，其包括将式 （3）使用包含选自镧系元素离子，碱土金属离子或钇离子的硼氢化物离子和金属离子的还原体系（或其盐）。 还原体系可以由硼氢化物（例如NaBH 4）和金属盐（例如CeCl 3）提供。 然后，如果需要，酯（2）可水解以得到母体酸。